»ï¼º¹ÙÀÌ¿À¿¡Çǽº(´ëÇ¥ÀÌ»ç °íÇѽ »çÀå)°¡ ¿ÃÇØ ºñ´ë¸éÀ¸·Î °³ÃֵǴ À¯·´ Á¾¾çÇÐȸ Á¤±â Çмú´ëȸ(ESMO Virtual Congress 2020)¿¡¼ ÇöÁö ½Ã°£ 9¿ù 14ÀϺÎÅÍ 18ÀϱîÁö ¿¸®´Â °¡»ó Àü½Ãȸ(Virtual Exhibition)¸¦ ÅëÇØ ‘¿¡À̺ó½Ã¿À(AYBINTIO®, ¾Æ¹Ù½ºÆ¾ ¹ÙÀÌ¿À½Ã¹Ð·¯, ¼ººÐ¸í º£¹Ù½ÃÁÖ¸¿)’ÀÇ »õ·Î¿î ¿¬±¸ °á°ú¸¦ °ø°³Çß´Ù.
»ï¼º¹ÙÀÌ¿À¿¡Çǽº´Â Áö³ ÇØ °°Àº Çà»ç¿¡¼ ‘¿¡À̺ó½Ã¿À’ÀÇ ±Û·Î¹ú ÀÓ»ó3»ó °á°ú¸¦ ¹ßÇ¥ÇÑ ¹Ù ÀÖÀ¸¸ç, ¿ÃÇØ´Â À̸¦ ¹ÙÅÁÀ¸·Î Ãß°¡ ºÐ¼® (Exploratory Analyses)À» ½Ç½ÃÇÏ¿© ¿À¸®Áö³Î ÀǾàÇ°°úÀÇ ÀÓ»óÀÇÇÐÀû µ¿µî¼ºÀ» ÀçÂ÷ ÀÔÁõÇÒ ¼ö ÀÖ´Â À¯ÀǹÌÇÑ µ¥ÀÌÅ͸¦ ¼öÁýÇß´Ù.
»ï¼º¹ÙÀÌ¿À¿¡Çǽº´Â ÀÓ»ó3»ó¿¡ Âü¿©Çß´ø ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC: non-small cell lung cancer) ȯÀÚ Áß ÀÓ»ó½ÃÇè ÇÁ·ÎÅäÄÝÀ» ÁؼöÇÑ ‘¼øÀÀ Áý´Ü(PPS: per-protocol set)’À¸·Î ºÐ·ùµÈ 665¸íÀ» ´ë»óÀ¸·Î ‘¿¡À̺ó½Ã¿À’¿Í ¿À¸®Áö³Î ÀǾàÇ° °£ Ãß°¡ÀûÀÎ ºñ±³ ºÐ¼®À» ½Ç½ÃÇß´Ù.
ù ¹ø°·Î, 24ÁÖ°£ÀÇ‘ÃÖ°í Àüü¹ÝÀÀ·ü(best ORR: Overall Response Rate)’¿¡¼ À¯ÀǹÌÇÑ Ä¡·á °æ°ú¸¦ È®ÀÎÇÒ ¼ö ÀÖ´Â 11ÁÖ ¹× 17ÁÖÂ÷ÀÇ µ¥ÀÌÅ͸¦ ºÐ¼®Çß´Ù.
ÃÖ°í Àüü¹ÝÀÀ·üÀ̶õ ƯÁ¤ ±â°£ µ¿¾È »çÀü¿¡ Á¤ÇØ ³õÀº ¹üÀ§ ÀÌ»óÀÇ Á¾¾ç °¨¼Ò¸¦ º¸ÀΠȯÀÚÀÇ ºñÀ²À» ¶æÇϸç, »ï¼º¹ÙÀÌ¿À¿¡Çǽº´Â °ú°Å ÃÑ 24ÁÖ°£ÀÇ ÃÖ°í Àüü¹ÝÀÀ·üÀ»‘¿¡À̺ó½Ã¿À’ ÀÓ»ó3»ó °á°úÀÇ 1Â÷ À¯È¿¼º Æò°¡ ÁöÇ¥·Î ÃøÁ¤ÇÑ ¹Ù ÀÖ´Ù.
±× °á°ú, 11ÁÖ ¹× 17ÁÖÂ÷¿¡ º¸ÀΑ¿¡À̺ó½Ã¿À’¿Í ¿À¸®Áö³Î ÀǾàÇ° °£ ÃÖ°í Àüü¹ÝÀÀ·ü À§Çèµµ Â÷ÀÌ(risk difference)´Â °¢°¢ 2.2%(95% CI:-4.6%, 9.1%) ¿Í 2.4%(95% CI: -5.1%, 10.0%)¿´°í, µÎ ÀǾàÇ° °£ À¯ÀǹÌÇÑ Â÷ÀÌÁ¡ÀÌ ¹ß»ýÇÏÁö ¾Ê¾Ò´Ù. µÎ ¹ø°·Î´Â ±âÁØÁ¡ ´ëºñ Á¾¾ç Å©±âÀÇ‘ÃÖ´ë º¯ÈÀ²(maximum percentage change)’À» ÃøÁ¤Çß´Ù. ÀÌ´Â Ä¡·á ½ÃÀÛ ½ÃÁ¡À» ±âÁØÀ¸·Î °¢ ÁÖÂ÷º°·Î Á¾¾çÀÌ °¡Àå Å©°Ô °¨¼ÒÇÑ ºñÀ²ÀÇ Æò±Õ°ªÀ» ±¸ÇÑ °ÍÀ¸·Î¼, ÀÌ °á°ú ¿ª½Ã ‘¿¡À̺ó½Ã¿À’¿Í ¿À¸®Áö³Î ÀǾàÇ° °£ À¯ÀǹÌÇÑ Â÷ÀÌÁ¡ÀÌ ¹ß»ýÇÏÁö ¾Ê¾Ò´Ù.
* ¼¼ºÎ µ¥ÀÌÅÍ Âü°í: »ï¼º¹ÙÀÌ¿À¿¡Çǽº ¿µ¹® º¸µµÀÚ·á ñé
https://www.samsungbioepis.com/en/newsroom/newsroomView.do?idx=193¤tPage=1
“…this abstract showed the risk difference in best ORR by 11 and 17 weeks was 2.2% (95% CI: -4.6%, 9.1%) and 2.4% (95% CI: -5.1%, 10.0%), respectively. Additionally, the mean of maximum percentage change from baseline in tumor burden by 24 weeks was -27.8% for AYBINTIO® and -27.3% for reference bevacizumab with a difference of 0.59% (p-value: 0.7452).”
»ï¼º¹ÙÀÌ¿À¿¡Çǽº°¡ ÁøÇàÇÑ ‘¿¡À̺ó½Ã¿À’ ÀÓ»ó 3»ó ÈÄ¼Ó ¿¬±¸°á°úÀÇ ÀÚ¼¼ÇÑ ³»¿ëÀº 17ÀÏ(ÇöÁö½Ã°£) e-Æ÷½ºÅÍ Çü½ÄÀ¸·Î ÁÖÃÖÃø µðÁöÅÐ Ç÷§ÆûÀ» ÅëÇØ °ø°³µÉ ¿¹Á¤ÀÌ´Ù.
»ï¼º¹ÙÀÌ¿À¿¡Çǽº °ü°èÀÚ´Â “ÀÓ»ó ½ÃÇèÀÇ ÈÄ¼Ó ¿¬±¸¸¦ ÅëÇØ ‘¿¡À̺ó½Ã¿À’¿Í ¿À¸®Áö³Î ÀǾàÇ° °£ ÀÇÇÐÀû È¿´ÉÀÌ µ¿µîÇÑ ¼öÁØÀÓÀ» ´Ù½Ã ÇÑ ¹ø ÀÔÁõÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ´ç»ç Á¦Ç°ÀÌ ´õ ¸¹Àº ȯÀڵ鿡°Ô ÇÕ¸®ÀûÀÌ°í È¿°úÀûÀÎ Ä¡·á ´ë¾ÈÀÌ µÉ ¼ö Àֱ⸦ ±â´ëÇÑ´Ù.”°í ÀüÇß´Ù.
ÇÑÆí, ‘¿¡À̺ó½Ã¿À’´Â Áö³ 8¿ù À¯·´¿¬ÇÕ ÁýÇàÀ§¿øȸ(EC: European Commission)·ÎºÎÅÍ ÆǸŠÇã°¡¸¦ ȹµæÇÑ ±¹³» ÃÖÃÊ·Î °³¹ßµÈ ‘¾Æ¹Ù½ºÆ¾(AVASTIN®)’ ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Ç°À¸·Î¼, »ï¼º¹ÙÀÌ¿À¿¡Çǽº´Â ¸¶ÄÉÆà ÆÄÆ®³Ê»ç MSD(¹Ì±¹ Merck)¿Í ÇÔ²² À¯·´ ÁÖ¿ä 5°³±¹(EU5: µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ)À» Áß½ÉÀ¸·Î ‘¿¡À̺ó½Ã¿À’ÀÇ º»°ÝÀûÀÎ ÆǸŠüÁ¦¿¡ µ¹ÀÔÇß´Ù.
ÇöÀç »ï¼º¹ÙÀÌ¿À¿¡Çǽº´Â À¯·´ ½ÃÀå¿¡¼ º£³×Æȸ®(BENEPALI®, ¿£ºê·¼ ¹ÙÀÌ¿À½Ã¹Ð·¯)’,‘ÀÓ¶öµð(IMRALDI® . È޹̶ó ¹ÙÀÌ¿À½Ã¹Ð·¯)’, ‘Çø¯»çºñ(FLIXABI®, ·¹¹ÌÄÉÀÌµå ¹ÙÀÌ¿À½Ã¹Ð·¯)’,‘¿ÂÆ®·çÀÜÆ®(ONTRUZANT®, Çã¼Áƾ ¹ÙÀÌ¿À½Ã¹Ð·¯)’¸¦ ÆǸÅÇÏ°í ÀÖÀ¸¸ç, ‘¿¡À̺ó½Ã¿À’ Ãâ½Ã¸¦ ÅëÇØ À¯·´¿¡¼ ÃÑ ´Ù¼¸ Á¾ÀÇ ¹ÙÀÌ¿ÀÀǾàÇ°À» ½ÃÀå¿¡ ¼±º¸ÀÌ°Ô µÆ´Ù.
Á¶¼ö¿µ ±âÀÚ bodo@emoneynews.co.kr
<ÀúÀÛ±ÇÀÚ © À̸Ӵϴº½º, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>